MAPT and Brain atrophy: For instance, in mouse models of Alzheimer's disease, overexpression of sFKN using rAAV in Tg4510 mice (but not in APP/PS1 mice) led to reduced tau phosphorylation and deposition, decreased neuronal loss and brain atrophy, and cognitive improvements [34, 35].